Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients

Iva Truxova,1 Lenka Kasikova,1,2 Cyril Salek,3,4 Michal Hensler,1 Daniel Lysak,5 Peter Holcek,1,2 Pavla Bilkova,1 Monika Holubova,6 Xiufen Chen,7 Romana Mikyskova,8 Milan Reinis,9 Marek Kovař,9 Barbora Tomalova,9 Justin P. Kline,7,10,11 Lorenzo Galluzzi,12,13,14,15,16 Radek Spisek1,2 and Jitka Fucikova1,2

1 Sotio, Prague, Czech Republic; 2 Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic; 3 Institute of Hematology and Blood Transfusion, Prague, Czech Republic; 4 Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; 5 Department of Hematology and Oncology, University Hospital in Pilsen, Czech Republic; 6 Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; 7 Department of Medicine, University of Chicago, Chicago, IL, USA; 8 Laboratory of Immunological and Tumour models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic; 9 Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic; 10 Committee on Immunology, University of Chicago, Chicago, IL, USA; 11 University of Chicago Comprehensive Cancer Center, Chicago, IL, USA; 12 Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; 13 Sandra and Edward Meyer Cancer Center, New York, NY, USA; 14 Caryl and Israel Engleman Institute for Precision Medicine, New York, NY, USA; 15 Department of Dermatology, Yale School of Medicine, New Haven, CT, USA and 16 Universite de Paris, Paris, France

© 2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.223933

Received: April 8, 2019.
Accepted: September 26, 2019.
Pre-published: October 3, 2019.
Correspondence: JITKA FUCIKOVA - fucikova@sotio.com
Supplementary data

Supplemental Methods

**Blood samples.** Peripheral blood samples were obtained before the onset of chemotherapy and upon complete remission after complete restoration of hematopoiesis (50-70 days after chemotherapy). Serum was collected and stored at -80 °C. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque PLUS (GE Healthcare) gradient centrifugation.

**Cell lines and reagents.** Chronic myelogenous leukemia K562 cells (ATCC) were cultured in IMDM (Gibco) containing 4 mM L-glutamine, 4.5 g/L glucose and supplemented with 10% fetal bovine serum (FBS, from PAA) and 100 U/mL penicillin plus 100 µg/mL streptomycin (Gibco). Mouse AML C1498 cells was purchased from ATCC and C1498 cells expressing CRT on the cell surface (C1498.CRT) were generated as described previously (21). C1498 cells were cultured in DMEM (Gibco) containing 4 mM L-glutamine, 4.5 g/L glucose and supplemented with 10% FBS, 100 U/mL penicillin plus 100 µg/mL streptomycin, and 50 µM 2-mercaptoethanol (Gibco). All cell lines were regularly tested for *Mycoplasma* by using MycoAlert® Mycoplasma Detection Kit (Lonza) and Spark reader (Tecan) detecting luminescence. The cell lines were used for experiments after 2 to 5 passages from thawing. Recombinant human calreticulin (rCRT, from Sino Biological Inc.) was added to either NK cell or whole PBMC cultures from heathy donors (HDs) to a final concentration of 5 µg/mL. Cells were incubated with rCRT overnight at 37 °C before analysis of cell phenotype and function by flow cytometry.

**Isolation of NK cells.** NK cells were isolated from fresh PBMCs from AML patients before the initiation of induction chemotherapy (n=10) and upon complete remission and complete restoration of hematopoiesis (n=10) by negative selection with the NK cell isolation kit
(Miltenyi Biotec) according to the manufacturer’s instructions. The purity of NK cells isolated from AML patients at diagnosis was increased by two-step pre-purification procedure including the exclusion of CD33+ malignant blasts, achieved with the EasySep human CD33 positive selection kit (STEMCELL Technologies), and the exclusion of CD34+ blasts, based on the CD34 MicroBead kit (Miltenyi Biotec). Freshly isolated NK cells were labeled with the Vybrant DiI cell labeling solution (Invitrogen) and maintained overnight in RPMI 1640 medium (Gibco) containing 10% AB human serum (Invitrogen) and supplemented with 200 U/mL IL-2 (PeproTech) for pre-activation. Alternatively, NK cells were isolated from PBMCs from HDs after overnight incubation with 5 μg/ml rCRT (Sino Biological Inc.) and used for subsequent cytotoxicity assay.

**NK cell cytotoxicity assay.** NK cells from AML patients or HDs were tested for their capacity to kill NK cell-sensitive K562 cells. NK cells labeled with Vybrant dye DiI were co-cultured with target DiD-labeled K562 cells in RPMI 1640 medium containing 10% AB human serum in 96-well U-bottom plates (Nunc) at two different effector:target cell ratios (10:1 and 5:1). After 4 h, cells were harvested, washed by PBS and co-stained with Annexin V and DAPI. Viability of target DiD+ K562 cells was determined by flow cytometry.

**Degranulation and IFN-γ production after in vitro stimulation.** To assess NK cell and T cell function in AML patients, fresh PBMCs were stimulated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA, from Sigma Aldrich) plus 1 μg/mL ionomycin or with K562 cells at PBMC:tumor cell ratio 10:1 plus overnight incubation with 200 U/mL IL-2 in the presence of anti-CD107a-FITC monoclonal antibody (BioLegend) for 1 h, followed by 3 h incubation with brefeldin A (BioLegend). Cells were then washed in PBS, stained with anti-CD45-PE (EXBIO), anti-CD3-AlexaFluor700 (EXBIO), anti-CD4-ECD (Beckman Coulter), anti-CD8-HV500 (BD Biosciences) and anti-CD56-PerCP-Cy5.5 monoclonal antibodies (BioLegend), fixed in fixation/permeabilization buffer (eBioscience), further permeabilized with permeabilization
buffer (eBioscience) and intracellularly stained with anti-IFN-γ-PE-Cy7 (eBioscience), anti-granzyme B-BrilliantViolet421 (BD Biosciences) and anti-perforin-APC monoclonal antibodies (BioLegend). We also determined NK cell and T cell function in the spleen and/or tumors in C57BL/6 (B6) mice after C1498.WT/CRT cell injection. Fresh mouse splenocytes and/or tumor cell suspension were stimulated with PMA plus Ionomycin (to assess NK cell function) and with PMA plus Ionomycin or Dynabeads Mouse T-Activator CD3/CD28 beads at bead-to-cell ratio of 1:1 (Life Technologies) (to assess T cell function) and stained with antimouse antibodies following the same protocol as described above. Alternatively, PBMCs or NK cells isolated from HDs were pre-incubated with 5 μg/mL rCRT overnight at 37 °C and stimulated and processed as described above.

**Mice.** C57BL/6 (B6) mice were obtained from the animal facility of the Institute of Physiology (Czech Academy of Sciences, CAS), v.v.i.. Mice were maintained in the conventional animal facility of Institute of Microbiology of CAS, v.v.i. and used for experiments when at 9-15 weeks of age. Mice were regularly screened for mouse hepatitis virus (MHV) and other common mouse pathogens, according to FELASA guidelines. All experiments were approved by the Animal Welfare Committee at the Institute of Microbiology of CAS, v.v.i.. To generate tumors *in vivo*, 1x10⁶ C1498.WT or C1498.CRT cells were inoculated s.c. into the lower right flank of B6 mice in 100 μL of PBS on day 0 (D0). Tumor size was measured every 2 days by standard laboratory caliper and determined according to the following formula: size= (length x weight) mm². Mice were sacrificed on D3 or D19 and spleen and tumors were harvested for analysis of functional status of NK cells (spleen on D3) and T cells (both spleen and tumors on D19) by flow cytometry.

**Circulating cytokine analysis in AML patients.** The levels of IFN-γ, IFN-α2, IL-21, IL-15, IL-7 and IL-3 in the serum of patients with AML in complete remission (n=60) were determined by Luminex assay (custom made MILLIPLEX® MAP 6-Plex Human Cytokine Magnetic Bead
Panel Kit; Merck Millipore) according to the manufacturer’s instructions. Data were acquired using Luminex MAGPIX.

**Isolation of RNA from PBMCs and reverse transcription.** Total RNA was isolated with the RNeasy Mini Kit (Qiagen). Cell lysate in RLT buffer enriched with 1% 2-mercaptoethanol was quickly thawed and processed as per manufacturer’s instructions, including a DNase I digestion step. RNA concentration and purity were determined using a NanoDrop 2000c (Thermo Scientific), and RNA integrity was assessed using an Agilent 2000 Bioanalyzer (Agilent). Purified RNA samples were stored at -80 °C until further use. RNA samples with an integrity number ≥ 7 were used for reverse transcription. cDNA for the detection of selected 46 genes associated with immune system, including NK cell genes, was synthesized from 200 ng of total RNA using the TATAA GrandScript cDNA Synthesis Kit (TATAA Biocenter).

**cDNA preamplification.** Ten microliters of 2-times diluted cDNA were used in a 50 μL preamplification reaction using a TATAA PreAmp GrandMaster® Mix and primers at final concentration of 40 nM per primer. The following thermal profile for targeted pre-amplification was implemented on a T100 Thermal Cycler (Bio-Rad): 95 °C for 3 min, followed by 14 cycles of amplification (95 °C for 20 s, 55 °C for 3 min and 72 °C for 20 s). After the final extended (10 min) elongation step, samples were immediately frozen and stored at -20 °C until analysis.

**High-throughput quantitative real-time PCR.** High-throughput qPCR was performed on the BioMark system using the 48.48 Dynamic Array Chip for Gene Expression and probe-based detection. Each 5 μL sample reaction contained 1 μL of 10-times diluted pre-amplification product, 2.74 μL Probe GrandMaster Mix (TATAA Biocenter), 0.25 μL 20X GE Sample Loading Reagent (Fluidigm), 0.01 μL ROX (Life Technologies, the final concentration in the sample mix was 50 nM) and DNA/DNAsese-free water. The 5 μL assay reaction mix contained 2.5 μL Assay Loading Reagent (Fluidigm) and 2.5 μL of a 5 μM mix of reverse and forward
primers plus 2.5 µM probes. Priming and loading of the dynamic array were performed according to the manufacturer’s instructions using the IFC controller HX. The temperature profile was thermal mixing at 50 °C for 2 min followed by 70 °C for 40 min and 25 °C for 10 min, hot start activation at 95 °C for 30 s and 40 cycles of amplification (95 °C for 10 s and 60 °C for 60 s). Melting curve analysis was performed in the range of 60 °C to 95 °C at 0.5 °C per second increments. Amplification data were analyzed with Fluidigm Real-Time PCR Analysis software, applying the linear derivative baseline subtraction method and a user-defined global threshold to obtain Cq values. Melting curve analysis was performed on all samples. Pre-amplification and Biomark’s measurement were performed at BIOCEV Gene Core Facility (Vestec, Prague).
Supplemental Figures

Supplemental Figure 1

(A) The percentage bone-marrow CD45CD3CD56+ NK cells in CRT\textsuperscript{Hi} \textit{versus} CRT\textsuperscript{Lo} AML patients before the induction chemotherapy (Prior, n=45) and at re-establishment of normal hematopoiesis (Recovery, n=10) determined by flow cytometry. Boxplots: lower quartile, median, upper quartile; whiskers, minimum, maximum; ns, not significant. (B) The frequency of CD45CD3CD56+ NK cells staining positively for inhibitory NK cell receptor ILT2 in CRT\textsuperscript{Hi} and CRT\textsuperscript{Lo} AML patients upon complete remission and re-establishment of normal hematopoiesis (Recovery, n=31) determined by flow cytometry. Boxplots: lower quartile,
median, upper quartile; whiskers, minimum, maximum. (C) Linear regression analysis between NK cell ligand gene \((MICA, ULBP2, PVR, PVRL2)\) mRNA levels and ER stress response gene \((ATF4, DDIT3\) and \(HSPA5\)) mRNA levels in 173 AML patients from the TGCA public database. R, Pearson correlation coefficient; ns, not significant. (D) Gating strategy for NK cells and their functional properties. The percentage of cells in each gate is reported.
(A, B) The effect of recombinant human calreticulin (rCRT, Sino Biological Inc.) on effector functions of isolated HD NK cells (n=8) or NK cells in HD PBMC mixture (n=8). Purified NK cells (A) or whole PBMCs (B) were pre-incubated with 5 μg/ml of rCRT overnight and subsequently stimulated by PMA + Ionomycin or K562 cell line for 4 h. The percentage of responding (IFN-γ⁺CD45⁺CD3⁻CD56⁺) NK cells was determined by flow cytometry. NK cells/PBMCs without rCRT and unstimulated NK cells/PBMCs were used as a negative controls. ns, not significant.
(A) Percentage of CD3−CD56+IFNγ+CD107+ and CD3−CD56+IFNγ+GZMB+ NK cells upon exposure to human myeloid DCs (mDCs) or plasmacytoid DCs (pDCs) activated by rCRT or polyI:C. (B) Expression levels of CD54, CD86 and MHC Class II molecules on CD11c+ cells exposed to rCRT or polyI:C for 24 hours. (C) Percentage of CD86+ or MHCII+ cells amongst mouse bone marrow-derived CD11c+ DCs upon cultivation with rCRT or CpG1826 for 24 hours. (D) Level of IL-12 secreted by mouse CD11c+ bone marrow-derived DCs after cultivation with rCRT or CpG1826 for 24 hours determined by ELISA.
Supplemental Figure 4

(A) Quantitative RT-PCR-assisted quantification of the expression levels of 46 genes associated with immune system in PBMCs from 20 CRT\textsuperscript{Hi} versus 21 CRT\textsuperscript{Lo} AML patients at recovery of normal hematopoiesis. (B, C) The percentage of IFN-\(\gamma\)\(^+\) CD8\(^+\) and CD4\(^+\) T cells and CD107a\(^+\)/GZMB\(^+\)CD8\(^+\) T cells (D) upon PMA + Ionomycin stimulation in 13 CRT\textsuperscript{Lo} and 13 CRT\textsuperscript{Hi} AML patients upon the restoration of normal hematopoiesis. Patient samples were analyzed by flow cytometry. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. ns, not significant. (E) The levels of IFN-\(\gamma\) in the sera of 28 CRT\textsuperscript{Hi} versus 29 CRT\textsuperscript{Lo} AML patients at recovery of normal hematopoiesis. The concentration of IFN-\(\gamma\) was determined by ELISA.
Supplemental tables

Supplemental Table 1. Anti-human antibodies used for flow cytometry.

| Parameter | source | Producer       | Clone       | Fluorochrome | Dilution |
|-----------|--------|----------------|-------------|--------------|----------|
| B7-H6     | mouse  | R&D Systems    | 875001      | PE           | 6:100    |
| CCR7      | mouse  | BioLegend      | G043H7      | PerCP-Cy5.5  | 6:100    |
| CD3       | mouse  | EXBIO          | MEM-57      | Alexa Fluor 700 | 5:100 |
| CD3       | mouse  | BD Biosciences | SK7         | AmCyan       | 6:100    |
| CD4       | mouse  | eBioscience    | RPA-T4      | PE-Cy7       | 5:100    |
| CD4       | mouse  | Beckman Coulter| SFC112T4D11 | ECD          | 5:100    |
| CD8       | mouse  | BD Biosciences | RPA-T8      | HV500        | 5:100    |
| CD11c     | mouse  | BioLegend      | 3.9         | Brilliant Violet 421 | 4:100 |
| CD11c     | mouse  | EXBIO          | BU15        | APC          | 6:100    |
| CD14      | mouse  | EXBIO          | MEM-15      | FITC         | 6:100    |
| CD16      | mouse  | BioLegend      | 3G8         | Pacific Blue | 6:100    |
| CD45      | mouse  | Life Technologies | HI30  | PE-Texas Red | 6:100    |
| CD45      | mouse  | EXBIO          | MEM-28      | PerCP        | 6:100    |
| CD45      | mouse  | BioLegend      | HI30        | Pacific Blue | 6:100    |
| CD45      | mouse  | EXBIO          | MEM-28      | PE           | 2:100    |
| CD56      | mouse  | BioLegend      | MEM-188     | PerCP-Cy5.5  | 6:100    |
| CD56      | mouse  | EXBIO          | MEM-188     | FITC         | 6:100    |
| CD86      | mouse  | BD Biosciences | FUN-1       | Alexa Fluor 700 | 6:100 |
| CD107a    | mouse  | BioLegend      | H4A3        | FITC         | 8:100    |
| CD112     | mouse  | R&D Systems    | 610603      | Alexa Fluor 700 | 6:100 |
| CD155     | mouse  | BioLegend      | SKII.4      | PE-Cy7       | 6:100    |
| CD158a/h/g| mouse  | eBioscience    | HP-MA4      | APC          | 6:100    |
| CD158b1/b2, j | mouse  | Beckman Coulter | GL183 | PE         | 6:100    |
| CD158e1   | mouse  | BioLegend      | DX9         | Brilliant Violet 421 | 6:100 |
| DNAM-1    | mouse  | BioLegend      | 11A8        | PE           | 6:100    |
| Granzyme B | mouse  | BD Biosciences | GB11        | Brilliant Violet 421 | 4:100 |
| HLA-DR    | mouse  | BD Biosciences | L243        | PE-Cy7       | 6:100    |
| IFN-γ     | mouse  | eBioscience    | 4S.B3       | PE-Cy7       | 1:100    |
| ILT2      | mouse  | BioLegend      | GHI/75      | PE-Cy7       | 6:100    |
| IL-15Ra   | mouse  | BioLegend      | JM7A4       | PE           | 6:100    |
| MICA/B    | mouse  | BioLegend      | GD4         | APC          | 1:100    |
| NKG2A     | mouse  | R&D Systems    | 131411      | Alexa Fluor 700 | 6:100    |
| Antibody   | Species | Vendor   | Clone | Reporter | Scale |
|------------|---------|----------|-------|----------|-------|
| NKG2D      | mouse   | BioLegend| 1D11  | PE-Cy7   | 6:100 |
| NKp30      | mouse   | BioLegend| P30-15| APC      | 6:100 |
| NKp46      | mouse   | BioLegend| 9E2   | Alexa Fluor 700 | 6:100 |
| NKp80      | mouse   | Miltenyi Biotec | dG9 | FITC     | 6:100 |
| Perforin   | mouse   | BioLegend| dG9   | APC      | 4:100 |
| ULBP 2/5/6 | mouse   | R&D Systems | 165903 | PerCP    | 4:100 |
Supplemental Table 2. Anti-mouse antibodies used for flow cytometry.

| Parameter | source              | Producer | Clone   | Fluorochrome | Dilution |
|-----------|---------------------|----------|---------|--------------|----------|
| CD45      | rat                 | eBioscience | 30-F11  | eFluor 506   | 4:100    |
| CD3       | armenian hamster    | BioLegend | 145-2C11| PerCP        | 4:100    |
| CD8a      | rat                 | eBioscience | 53-6.7  | Alexa Fluor 700 | 4:100    |
| NK1.1     | mouse               | eBioscience | PK136   | PE-Cy7      | 4:100    |
| CD107a    | rat                 | eBioscience | 1D4B   | PErCP-eFluor 710 | 4:100    |
| CD107a    | rat                 | eBioscience | 1D4B   | eFluor 450  | 4:100    |
| IFN-γ     | rat                 | eBioscience | XMG1.2  | PE          | 4:100    |
| Perforin  | rat                 | eBioscience | eBioOMAK-D | APC        | 4:100    |
| Granzyme B| rat                 | eBioscience | NGZB   | PE-Cy7      | 4:100    |
| CD86      | rat                 | BD Bioscience | GL-1  | PE          | 1:100    |
| I-A(b) MHCII | armenian hamster | BD Bioscience | N418  | BV421       | 1:100    |
Supplemental Table 3. Immune system-related genes evaluated by quantitative RT-PCR in AML patients upon restoration of normal hematopoiesis.

| NK receptors | NK ligands | Inhibitory molecules | T cells | DC receptors | Cytokines | Cytotoxicity |
|--------------|------------|-----------------------|---------|--------------|-----------|-------------|
| FCGR3AB      | ULBP2      | PD1                   | CD3E    | LRP1         | IL12A     | CD69        |
| CD226        | PVR        | PDL1                  | CD8A    | IL15         | IL15      | FAS         |
| NCR1         | NECTIN2    | TIM3                  | CD4     | IL18         | IL18      | FASLG       |
| NCR3         |            | LAG3                  | CD40    | IFNA1        | IFNA1     | TNFRSF10A   |
| KLRF1        |            | CTLA4                 | CD40L   | IFNB1        | IFNB1     | TNFRSF10B   |
| KLRK1        |            |                       | ICOS    |              |           | TNFSF10     |
| KLRC1        |            |                       | CD28    |              |           | PRF1        |
| LILRB1       |            |                       | CCL5    |              |           | GZMB        |
|              |            |                       | CCR4    |              |           | IFNG        |
|              |            |                       | CCR5    |              |           | CXCL10      |
|              |            |                       |         |              |           | CXCL16      |
|              |            |                       |         |              |           | TNF         |